Bausch Health Cos Inc. (NYSE:BHC) Director John Paulson Acquires 86,409 Shares

Key Points

• Bausch Health Cos Inc. Director John Paulson purchased $610,047.54 worth of stock, acquiring 86,409 shares at an average cost of $7.06 per share.
• The company recently reported a 0.90 EPS for the quarter, which missed the consensus estimate of $0.97, despite generating $2.57 billion in revenue.
• JPMorgan Chase & Co. has significantly increased its stake in Bausch Health, raising it by 1,246.0% during the 4th quarter, now owning 19,840 shares valued at $160,000.

Bausch Health Cos Inc. (NYSE:BHC - Get Free Report) Director John Paulson acquired 86,409 shares of Bausch Health Cos stock in a transaction dated Wednesday, August 13th. The stock was bought at an average price of $7.06 per share, with a total value of $610,047.54. Following the completion of the purchase, the director directly owned 36,034,751 shares in the company, valued at $254,405,342.06. This represents a 0.24% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.

John Paulson also recently made the following trade(s):

• On Thursday, August 14th, John Paulson purchased 34,721,118 shares of Bausch Health Cos stock. The shares were bought at an average cost of $9.00 per share, with a total value of $312,490,062.00.
• On Tuesday, August 12th, John Paulson purchased 1,156,640 shares of Bausch Health Cos stock. The stock was bought at an average price of $6.88 per share, with a total value of $7,957,683.20.
• On Monday, August 11th, John Paulson acquired 2,000,000 shares of Bausch Health Cos stock. The shares were bought at an average cost of $6.35 per share, for a total transaction of $12,700,000.00.
• On Friday, June 13th, John Paulson acquired 3,564,059 shares of Bausch Health Cos stock. The shares were bought at an average price of $5.94 per share, with a total value of $21,170,510.46.
• On Thursday, June 12th, John Paulson bought 1,005,376 shares of Bausch Health Cos stock. The shares were purchased at an average price of $5.47 per share, for a total transaction of $5,499,406.72.
• On Wednesday, June 11th, John Paulson purchased 1,029,098 shares of Bausch Health Cos stock. The stock was purchased at an average price of $5.24 per share, with a total value of $5,392,473.52.
• On Tuesday, June 10th, John Paulson acquired 754,134 shares of Bausch Health Cos stock. The stock was purchased at an average cost of $5.05 per share, with a total value of $3,808,376.70.

Bausch Health Cos Price Performance

BHC traded down $0.26 during trading on Monday, reaching $8.09. 1,422,923 shares of the company traded hands, compared to its average volume of 2,691,043. The company has a market cap of $2.99 billion, a P/E ratio of 31.21 and a beta of 0.41. The company has a debt-to-equity ratio of 141.90, a quick ratio of 0.98 and a current ratio of 1.31. Bausch Health Cos Inc. has a 12-month low of $4.25 and a 12-month high of $9.85. The firm has a fifty day simple moving average of $6.38 and a 200 day simple moving average of $6.01.

Bausch Health Cos (NYSE:BHC - Get Free Report) last issued its earnings results on Wednesday, July 30th. The company reported $0.90 earnings per share for the quarter, missing analysts' consensus estimates of $0.97 by ($0.07). The company had revenue of $2.57 billion for the quarter, compared to the consensus estimate of $2.47 billion. Bausch Health Cos had a negative return on equity of 852.36% and a net margin of 0.99%. On average, equities analysts forecast that Bausch Health Cos Inc. will post 4.41 EPS for the current year.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. Wall Street Zen raised shares of Bausch Health Cos from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Royal Bank Of Canada boosted their price objective on Bausch Health Cos from $8.50 to $10.00 and gave the company a "sector perform" rating in a research report on Friday, May 2nd.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in BHC. Cary Street Partners Financial LLC bought a new stake in shares of Bausch Health Cos in the first quarter worth about $27,000. Caitong International Asset Management Co. Ltd purchased a new position in Bausch Health Cos during the 1st quarter valued at approximately $27,000. SBI Securities Co. Ltd. grew its holdings in Bausch Health Cos by 244.2% during the 1st quarter. SBI Securities Co. Ltd. now owns 4,230 shares of the company's stock valued at $27,000 after buying an additional 3,001 shares in the last quarter. Russell Investments Group Ltd. increased its stake in Bausch Health Cos by 65.9% in the 2nd quarter. Russell Investments Group Ltd. now owns 7,819 shares of the company's stock worth $51,000 after acquiring an additional 3,106 shares during the last quarter. Finally, Wealthquest Corp purchased a new stake in shares of Bausch Health Cos during the 1st quarter worth approximately $58,000. Institutional investors own 78.65% of the company's stock.

About Bausch Health Cos

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.